Vaccines

New Centers for Disease Control and Prevention (CDC) data show rising early-season influenza activity, moderate 2024–2025 vaccine effectiveness, and updated 2025–2026 recommendations that include trivalent, thimerosal-free single-dose formulations and expanded access to FluMist.

James Conway, MD, describes how full vs partial repeal of nonmedical school-entry exemptions is associated with kindergarten vaccination and exemption trends.

Large international study reports higher A-strain protection and acceptable safety profile for quadrivalent RNA influenza vaccine.

A review of vaccine safety and effectiveness conducted by the Vaccine Integrity Project, independent of the CDC's ACIP, reflects its stated purpose as "dedicated to safeguarding vaccine use in the US."

Infectious disease specialists conducted a review of vaccine safety and effectiveness independent of the ACIP to inform vaccinating against COVID-19, RSV, and influenza during this ongoing respiratory virus season.

Seven months of clinical data corroborated emergency authorization of 2024-2025 mRNA COVID-19 vaccines for circulating JN.1 subvariants.

RSV vaccines protected older adults against RSV-related hospitalization over 2 seasons, although with less effectiveness for those with immunocompromise or cardiovascular disease.

Dynavax and Vaxart have entered into a license and collaboration agreement to advance Vaxart’s investigational oral COVID-19 vaccine, with phase 2b data expected in late 2026.

This week, meet SIDP's president-elect, the connection between UTIs and meat, a COVID-19 vaccine alternative, and other highlights from IDWeek.

Moderna’s investigational cytomegalovirus (CMV) vaccine, mRNA-1647, did not meet its primary endpoint in a phase 3 trial, leading the company to discontinue its congenital CMV program while continuing studies in transplant patients.

This week, learn about the Center for Discovery and Innovation's research around vaccines and the next generation of rifamycins, as well as results from a Cefiderocol study looking at healthcare-associated Gram-negative bloodstream infections and more.

This week, learn about the Center for Discovery and Innovation's research around antivirals, the hepatitis C bill in Congress, how AI is influencing antimicrobial development, and more.

This week, there are C diff and hepatitis roundup reports, how COVID-19 has disrupted traditional respiratory virus patterns with summer surges now preceding the typical winter influenza season, a review of a trial comparing dalbavancin with standard intravenous therapy for Staphylococcus aureus, and more.

Low vaccination rates did not rise sufficiently to attain "herd immunity" after a measles outbreak in a region in which it had been eliminated.

This week, review of ACIP’s latest decisions, analysis links food insecurity with higher long COVID risk, and advocacy for immune-informed antibiotic development with updated susceptibility testing.

Georges C.Benjamin, MD, executive director of the American Public Health Association, details practical implications for clinical teams.

Merck’s single-dose, weight-independent antibody provides about five months of protection; EC decision pending, and it is already FDA approved in the United States.

Infectious disease pediatrician Sharon Nachman, MD, offers insights on what is already being done in clinical practice with regards to vaccines, the CDC committee's votes on the MMRV and hepatitis b vaccines, and understanding how they will affect these immunizations going forward.

ACIP keeps broad access to COVID-19 vaccines, requests stronger informed-consent materials, and does not require prescriptions.

The non-vote leaves the current immunization recommendation in place, but led to further debate amongst the CDC's ACIP panelists on the hepatitis B vaccine as well as questioning the current process of the delivery of data and whether they would be utilizing working groups and grading studies.

The committee voted to change the MMRV vaccine recommendation, left panelists uncertain around a second MMRV immunization vote, and delayed the hepatitis B vaccine vote until Friday.

Today’s MMWR recommends twice-yearly subcutaneous lenacapavir for people ≥35 kg, citing PURPOSE-1/2 efficacy, a favorable safety profile with mostly mild to moderate injection-site reactions, and potential adherence benefits.

Catherine M. Stein, Evelyn Griffin, Hilary Blackburn, Kirk Milhoan, and Raymond Pollak join ACIP as the panel prepares to vote on MMRV, hepatitis B, and COVID-19 recommendations following the June reconstitution.

The Los Angeles County Department of Public Health updated the public on the specific local case and reminds everyone of the importance of vaccination to protect the community.

Merck reported the results for its phase 3 trial for its vaccine, Capvaxive, which was found to be noninferior to the pneumococcal 23-valent polysaccharide vaccine (PPSV23) for each of the 12 serotypes shared between the vaccines.